On May 5, 2022 Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, reported that Jonathan Drachman, M.D., Chief Executive Officer, will participate in two upcoming investor conferences (Press release, Neoleukin Therapeutics, MAY 5, 2022, View Source [SID1234613696]). Presentation details are as follows:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
BofA Securities 2022 Healthcare Conference – Las Vegas, NV
Fireside chat
Wednesday May 11, 2022, at 1:20 p.m. Pacific
H.C. Wainwright Global Investment Conference – Miami, FL
Company presentation
Wednesday, May 25, 2022, at 12:30 p.m. Eastern
The webcast presentations can be accessed from the investors section of the Neoleukin website at View Source Archived replays will also be available on the company website for at least 30 days following the event.